When CVS announced that it would replace biological analogues in its health care catalog from next year

Source: on August 8, 2016, when CVs, the US drug welfare manager, will delete Sanofi's main insulin drugs from the medical insurance catalog it reimburses on behalf of the medical insurance company, it will undoubtedly be a major blow to Sanofi's key diabetes business in France CVS said it would switch to the cheaper biologicals like basilar from 2017 Bioequivalent drugs are cheap versions of protein based biotechnological drugs, such as when they come, that are no longer patented Bioequivalent drugs cannot replicate as accurately as traditional chemical drugs, but they are shown to be equivalent to reference drugs in terms of efficacy and side effects CVs and other U.S drug welfare managers help private medical insurance companies negotiate better drug prices from drug manufacturers At the same time, they also draw up so-called drug lists, which are the drug catalogs they reimburse for the insurance companies they serve CVs, which has about 80 million program members, recently announced a major adjustment to its drug list, saying it would save a lot of money The company also said it no longer reimbursed toujeo, Sanofi's new diabetes drug "Sanofi was disappointed with the decision Doctors and patients should have a choice about their treatment, "the French group said in an electronic statement "We will continue our discounts with other insurers," he said, adding that CVS's announcement would not change the group's expectations The patent in the U.S expired in 2015 The U.S is the largest drug market in the world Sanofi hopes to recover the decline of its diabetes drug sales through toujeo, which was launched in March 2015 Novartis and actelon in Switzerland have also been hit by CVS's new health care catalog In a study, analysts at Citigroup said CVS's new health care catalog represented the era of bio analogues Evans, an analyst at Kepler Seinfeld group, said CVS's decision means investors will be ready for the end of the era of Sinochem, limiting sales of diabetes drugs to a 4-8% annual decline by 2018 Sanofi last week released a lower second quarter sales and profit report, which was partly affected by the company's diabetes business, which saw its sales fall 3.5% to $1.8 billion at constant exchange rates When asked when the threat of bio similar drugs in the United States will come, Gunter, director of Sanofi's diabetes business, told investors that it's hard to imagine thousands of patients switching to bio similar drugs, given the presence of master patients